High Expectations f...
Health Care: Drugs
Alkermes PLC (ALKS: NASDAQ)
$18.88 -0.38 | -1.97%
02/08/12 - 04:00 PM ET
820.03K / 805.20K
Vol / Avg. Vol:19.20 / 19.26
Open / Prev. Close:18.66 - 19.38
Today's Range:11.86 - 20.00
52 Wk Range:30.78%
Performance YTD:TheStreet Rating:
Portfolios with ALKS
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Usergterryburns
- Usermitetwo Portfolio 1
- ContributorBreakout Stocks Of The Week...
- Contributor10 Biotech Stocks Facing FD...
- UserPART 5 JPMorgan 28th Annual...
- UserWilliam T Blanchard - Medical
- Usergkraz
- UserPART 5 JPMorgan 27th Annual...
Latest ALKS Headlines from TheStreet
- The Curse of Amylin's Diabetes Drug Approval 02.06.12 | 08:02 am
- PharMerica, Amylin: After-Hours Trading 01.27.12 | 06:01 pm
- Third Time's The Charm for Approval of Amylin Diabetes Drug 01.27.12 | 03:01 pm
- 7 Stocks Rising on Huge Volume 01.25.12 | 02:01 pm
- UBS: 6 Specialty Pharma Picks to Watch 01.21.12 | 07:01 am
- Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
- Divorce! Amylin Pharma and Lilly Call It Quits Over Diabetes Drug 11.08.11 | 07:11 am
- Insiders Trading OPK, MSCC, KRA, ALKS 10.05.11 | 09:10 am
- Alkermes Closes Merger, Lands New Contract 09.19.11 | 12:09 pm
- 3 Stocks I Saw on TV, August 3 08.03.11 | 10:08 am
Press Releases for ALKS
- Alkermes’ Corporate Presentation To Be Webcast At The 14th Annual BIO CEO & Investor Conference - Business Wire 02.06.12 | 04:02 pm
- Alkermes Plc Reports Third Quarter Fiscal 2012 Financial Results - Business Wire 02.02.12 | 07:02 am
- Alkermes Initiates Open-Label Pilot Study Of VIVITROL® To Evaluate Impact On Re-Arrest And Re-Incarceration In Offenders With History Of Opioid Dependence - Business Wire 01.31.12 | 07:01 am
- Alkermes To Host Conference Call To Discuss Financial Results For Third Quarter Of Fiscal 2012 - Business Wire 01.26.12 | 04:01 pm
- Alkermes Announces Positive Results From Clinical Study Of ALKS 5461 For Major Depressive Disorder - Business Wire 01.04.12 | 07:01 am
- Alkermes’ Corporate Presentation To Be Webcast At The 30th Annual J.P. Morgan Healthcare Conference - Business Wire 01.03.12 | 07:01 am
- Alkermes Initiates Phase 3 Clinical Study Of ALKS 9070 For Treatment Of Schizophrenia - Business Wire 12.19.11 | 07:12 am
- Alkermes’ Corporate Presentation To Be Webcast At The NASDAQ OMX 27th Investor Program - Business Wire 11.29.11 | 04:11 pm
- New Long-Term Data On VIVITROL® Showed Sustained Efficacy And Safety Over 18 Months Of Treatment - Business Wire 11.09.11 | 07:11 am
- Alkermes’ Corporate Presentation To Be Webcast At Lazard Capital Markets 8th Annual Healthcare Conference - Business Wire 11.08.11 | 04:11 pm
Partner Headlines for ALKS
- Novo Nordisk Posts Solid 4Q - Analyst Blog - Zacks 02.06.12 | 10:02 am
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company - Press Releases - Zacks 02.06.12 | 09:02 am
- Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon Approval - Benzinga 02.02.12 | 01:02 pm
- CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous Story Clarified - Benzinga 01.11.12 | 04:01 pm
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan Corporation, Sprint, AT&T and Verizon - Press Releases - Zacks 11.16.11 | 09:11 am
- Healthcare Sector: Noteworthy Insider Buys And Sells - Seeking Alpha 11.08.11 | 09:11 am
- 9 Buy And 6 Sell Ideas By Cramer, Part I - Seeking Alpha 10.12.11 | 08:10 am
- Strong Insider Selling: A Signal For Investors To Sell As Well? - Seeking Alpha 10.11.11 | 09:10 am
- Insider Buys and Sells: Opko Health, RightNow Technologies - Seeking Alpha 10.09.11 | 07:10 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 10.03.11 | 09:10 am
